complication or loss of their tissue expander remains unclear. [5] [6] [7] In a retrospective study of 54 patients who had a tissue expander complication and went on to implant placement, Adkinson et al. suggest that patients with a tissue expander complication are three times more likely to have a subsequent complication and nine times more likely to lose their prosthesis. 6 However, Spear et al. report that 12 of 13 patients (92 percent) had a successful reconstruction nearly 2 years after implant placement despite having a previous tissue expander complication. 5 Similarly, Halvorson et al. showed that eight of nine patients (89 percent) were able to keep an implant, although two patients developed late contracture. 8 These studies are small, retrospective case series with short durations of followup and minimal bias analysis. 9 Consequently, few recommendations exist for how best to manage or counsel a patient that experiences a complication of her tissue expander but still desires implantbased reconstruction.
The study reviews a single center's 10-year experience with tissue expander complications and subsequent implant-based breast reconstruction. Our aim was to determine the incidence of implant loss after tissue expander complications and identify factors for implant-based reconstructive success or failure following complications. Secondary analyses also describe the causes of tissue expander complications in this patient series and culture results among women with infections.
PATIENTS AND METHODS

Study Sample
Following institutional review board approval (201308013), data were retrospectively collected from the medical record. All patients who underwent mastectomy and breast reconstruction with tissue expander placement from February of 2003 to May of 2013 at the Siteman Cancer Center in St. Louis, Missouri, were retrospectively identified using the physician billing database of Washington University School of Medicine in St. Louis. Patients that had mastectomy and tissue expander placement but did not experience a subsequent complication were then excluded from further study.
Study Design
Our primary analysis compared patients who did or did not have a complication of their permanent implant after having a complication with their tissue expander. The primary outcome was removal of the permanent implant. Patient and surgical factors were compared between patients who did or did not have a second complication using univariate and multivariate logistic regression. Cancer, radiation therapy, and complication laterality were taken into account in all analyses, as a complication associated with radiation of the right tissue expander would not necessarily have any bearing on a left-side permanent implant complication.
As patients offered a permanent implant without autologous tissue flap were subject to surgeon selection bias, we first characterize the patients in our primary analysis with demographic analysis of all patients included in the study. We call this "patient selection analysis." For this analysis, patients were divided into three categories: autologous reconstruction (women who had any autologous flap with or without implant placement), implant-only reconstruction (women who had an implant placed without a flap), and no further reconstruction. Patient and surgical factors were compared between groups. Finally, we perform a secondary analysis of the tissue expander complications experienced by all women included in this study. We call this "complications analysis." This analysis is intended to further characterize the population of women in this study, allowing readers to decide whether our results are generalizable to their patient population.
Patient and surgical factors considered important for analysis included patient age at the time of reconstruction, body mass index, diabetes mellitus, and smoking status (i.e., never, prior, and current). Clinical and surgical information included laterality of the breast reconstruction, laterality of complications, acellular dermal matrix use, chemotherapy, postmastectomy radiotherapy, premature tissue expander removal, permanent implant removal, and duration of reconstructive followup. When applicable, the time from mastectomy to radiotherapy, the time from mastectomy to delayed tissue expander placement, and the time from tissue expander placement to implant exchange were recorded. For premature explantation of the tissue expander or implant, the time from device placement to removal and the reason for removal were noted. Infection was defined as resumption of oral antibiotics after routine postoperative administration, readmission for intravenous antibiotics, and/or explantation. The decision to admit for intravenous antibiotics was based on surgeon preference that included consideration of failure to improve on oral antibiotics, Plastic and Reconstructive Surgery • January 2019 fever, pitting edema of the skin, social support, and travel distance. Mastectomy skin flap necrosis was defined as full-thickness skin loss requiring intervention, hematoma was defined as bleeding requiring reoperation, seroma was defined as fluid collection requiring drainage, and capsular contracture was defined as a documented Baker grade III or IV contracture that required operative intervention with capsulectomy.
Reconstructive Technique
Chemotherapy and radiation therapy were administered according to the recommendations of the medical and radiation oncologists. For patients who received neoadjuvant chemotherapy, mastectomy was delayed at least 4 weeks from the last chemotherapy treatment. Patients received a single dose of prophylactic intravenous antibiotics within 1 hour before incision for all operations. At the time of initial breast reconstruction, the tissue expander was placed beneath the pectoralis major, serratus anterior, and rectus fascia, or beneath the pectoralis major muscle and acellular dermal matrix. Tissue expanders were filled with a variable volume at the time of insertion, and further expansion commenced 3 to 4 weeks after surgery in the absence of wound healing delays or infection. Tissue expansion was completed before radiotherapy in all cases, except for patients who underwent delayed reconstruction. At the time of tissue expander exchange to a permanent implant, capsulotomy or capsulectomy was always performed. Two drains were always placed at the time of tissue expander placement and no drains or one drain was placed at implant exchange. Patients with a drain were always kept on prophylactic oral antibiotics-either cephalexin, trimethoprim-sulfamethoxazole, or doxycyclineuntil it was removed.
Statistical Analysis
Categorical variables were compared between groups using Pearson's chi-square, the MannWhitney U test, or Kruskal-Wallis H test. One-way analysis of variance or the t test was used to compare groups when variables were continuous and normally distributed. A post hoc Tukey correction was used when more than two groups were compared. Logistic regression models evaluated associations between patient and surgical factors and implant failure accounting for breast laterality, confounding factors such as timing of reconstruction, acellular dermal matrix use, and patient variables selected based on literature review. Confounders were selected based on literature review and removed from the model in a backward stepwise manner based on significance within the model or a change of the beta for tissue expander removal cause of more than 10 percent. 10 Statistical analyses were performed using IBM SPSS Version 23 (IBM Corp., Armonk, N.Y.) with significance set at p < 0.05.
RESULTS
Patient Characteristics
Nine hundred fifty-one women received 1453 tissue expanders (502 bilateral and 449 unilateral) between 2003 and 2013. One hundred seventyeight women (19 percent) had a complication of their tissue expander, or had their tissue expander removed before completing reconstruction. Nine women (1 percent) that requested their tissue expanders be removed and five women (0.5 percent) that had cancer progression requiring premature tissue expander removal were excluded from analysis. Two women (0.2 percent) were lost to follow-up before final reconstruction but after tissue expander removal and excluded from analysis. The complication rate among patients decreased significantly over the study period from 37 percent (95 percent CI, 0.31 to 0.43 percent) among the first quartile to 23 percent (95 percent CI, 0.17 to 0.29 percent) among the final quartile (p < 0.05).
One hundred sixty-two women (17 percent) were included in this study (Fig. 1) . Mean follow-up duration among these women was 8.3 ± 3.1 years (range, 4.0 to 14.0 years). One hundred forty-eight women (91 percent) had a tissue expander complication in one breast and 14 women (9 percent) had a tissue expander complication in both breasts.
Following tissue expander complications, 48 women (30 percent) went on to have a second tissue expander or implant placed (Fig. 2) , 47 women (29 percent) went on to an autologous reconstruction (Fig. 3) , and 67 women (41 percent) had no further reconstruction. Twentyseven women (17 percent) in the autologous reconstruction group had an implant along with a latissimus flap. None experienced further complications with their implant. Twenty women (12 percent) had an autologous reconstruction without implant. Autologous flaps used included pedicled latissimus dorsi, pedicled transverse rectus abdominis musculocutaneous (TRAM), muscle-sparing TRAM, deep inferior epigastric perforator (DIEP), and superficial inferior epigastric artery flaps.
Among the 162 women included in this study, 149 (92 percent) underwent immediate tissue expander placement and 13 women (8 percent) underwent delayed tissue expander placement. The median time to tissue expander placement in patients with delayed placement was 122 days (interquartile range, 71 to 465 days; range, 14 to 2199 days). Women who had delayed tissue expander insertion were significantly more likely to have had adjuvant chemotherapy (p < 0.01) than women with immediate tissue expander insertion. Their other demographic characteristics, cancer details, and comorbidities did not differ significantly.
The first case of acellular dermal matrix use among patients included in this study occurred in 2004. After 2005, only two cases were performed without using acellular dermal matrix. Patients with acellular dermal matrix were more likely to smoke than those without acellular dermal matrix (38 percent versus 16 percent, respectively; p < 0.01) and to have a shorter duration of followup (7.1 versus 11.7 years, respectively; p < 0.01). There were no other significant differences in age, body mass index, comorbidities, time to completion of reconstruction, or likelihood of permanent implant loss among patients with or without acellular dermal matrix.
Patient Selection Analysis
Following tissue expander complications, selected patients were offered another attempt at implant-based reconstruction. No significant differences were seen between patients who went on to repeated alloplastic reconstruction, autologous reconstruction, and no further reconstruction (Table 1) . However, patients offered a second attempt at implant-based reconstruction were marginally less likely to have had radiation therapy (p = 0.06). The median time to implant placement after initial tissue expander placement was 316 days (interquartile range, 203 to 534 days).
Permanent Implant Outcomes following Tissue Expander Infection
Fourteen of 48 women (29 percent) who had an implant placed subsequently had an implant complication requiring removal. The median time to implant removal was 48 days (interquartile range, 33 to 277 days; range, 8 to 3817 days). Four of these women (8 percent) eventually had another implant placed without further complication; in total, 38 of 48 women (79 percent) completed their reconstruction with a permanent implant. Three women (6 percent) went on to undergo autologous reconstruction. The remaining seven women (15 percent) underwent no further reconstruction (Fig. 4) . Among women who went on to have an implant placed, age, race, body mass index, diabetes mellitus, smoking status, stage, radiation therapy status, chemotherapy status, acellular dermal matrix use, cause for tissue expander removal, and cultures at the time of tissue expander removal did not make a significant difference for final success of The most common cause for implant removal was infection [five patients (34 percent)], followed by wound dehiscence/exposure [four patients (29 percent)]. Mastectomy flap necrosis, capsular contracture, malposition, and pain each resulted in removal of implant(s) in one patient (7 percent for each patient). One further patient (7 percent) requested implant removal without pathologic cause. In all but one case, the side of tissue expander complication was the same as the side of the implant complication.
Tissue Expander Complications
Among the 162 women included in this study, 150 (93 percent) required tissue expander explantation. Twelve women (7 percent) were placed on intravenous antibiotics for cellulitis and subsequently had their tissue expander exchanged for an implant without needing a premature tissue expander explantation. Seventy-six women (47 percent) were placed on intravenous antibiotics for cellulitis before having their tissue expander explanted. The most common cause of tissue expander explantation was infection [85 women (52 percent)], followed by mastectomy flap necrosis, implant exposure or wound dehiscence, implant leak, deflation or rupture, seroma, pain, hematoma, and capsular contracture ( Table 2 ). The median time to intravenous antibiotics for breast cellulitis was 38 days (interquartile range, 25 to 87 days; range, 5 to 938 days). The median time to tissue expander removal was 59 days (interquartile range, 28 to 145; range, 4 to 940 days).
Fifty-eight of 85 women (68 percent) required explantation of their infected tissue expander a median of 2 days (interquartile range, 1 to 3 days) after starting intravenous antibiotics. Fourteen women (16 percent) initially responded to intravenous antibiotics followed by 15.5 days (interquartile range, 8.5 to 23.8 days) of oral antibiotics but still required tissue expander removal 
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Among the 12 women whose infections resolved on antibiotics and whose tissue expanders did not require premature removal, eight of 12 (66 percent) had a successful implant-based reconstruction without further complications. Two women (17 percent) had a successful autologous reconstruction. Only one woman (8 percent) required subsequent removal of her implant for infection. Notably, her infection was methicillinresistant Staphylococcus aureus and never fully resolved before implant exchange (Table 3) .
Cultures from 82 patients were sent (81 patients at the time of tissue expander removal, and one patient who received only intravenous antibiotics). Cultures in 29 patients had no growth. Methicillin-sensitive S. aureus was the most common bacterial isolate [32 of 82 cultures (39 percent)]. Pseudomonas aeruginosa was the second most common isolate [six cultures (7 percent)] (Table 4) .
DISCUSSION
This study of outcomes of implant-based reconstruction following a tissue expander complication demonstrates that implant-based reconstruction is still successful in most women [38 of 48 (79 percent)]. Among the subgroup of women whose infection resolved without the need for tissue expander explantation and went on to prosthetic reconstruction, eight of nine (89 percent) recovered without further infectious complications. Our analysis failed to show any significant predictors of implant failure. This suggests that it is reasonable to offer a second attempt at alloplastic reconstruction to women who are not candidates for, or wish to avoid, autologous reconstruction. These results confirm the findings of prior studies and provide a larger cohort than any prior series. 5, 6, 8 Unlike prior studies, our analysis also accounts for laterality, improving the accuracy of analysis. Although our success rate was lower than prior series, our follow-up period was much longer (minimum follow-up, 4 years; mean follow-up, 8 years) and therefore likely catches late complications that were missed in prior studies. Moreover, unlike the works of Spear et al. or Halvorson et al., 5, 8 our results support the prior work of Adkinson et al. 6 that suggests that patients who experience a tissue expander complication are at three times the risk of permanent implant complication and nine times more likely to have definitive implant loss. Our reconstructive failure rate of 21 percent among these women was higher than historically reported rates of 0.7 to 7.1 percent, but our results make intuitive sense. 2, 11, 12 Consequently, patients considering alloplastic reconstruction after tissue expander complications should be informed of the increased risk of failure.
Our results do not support the findings of Adkinson et al. that tobacco use and radiation therapy were associated with an increased risk of complications in this population. 6 These results are not exactly comparable because Adkinson et al. consider all tissue expander patients rather than just those with complications, and they do not parse out those who have had a tissue expander, versus an implant, or versus a tissue expander then implant complication. Moreover, the methodology of their analysis was not fully described and did not mention correcting for multiple comparisons. Therefore, we would still consider offering a second attempt at implant-based reconstruction to women who smoke or who have undergone ipsilateral radiation therapy, although we would certainly counsel them to stop smoking. Our series does not control for factors such as soft-tissue laxity, donor-site adequacy, and patient willingness to consider an autologous flap and is therefore subject to significant bias. We routinely encourage patients with poor-quality skin or severe radiation damage to undergo autologous reconstruction with or without implants. Our acceptable results with a second attempt at prosthetic reconstruction, then, may be largely attributable to favorable patient selection and not generalizable to all patients with a failed prosthesis.
We no longer routinely keep our patients with drains on antibiotic prophylaxis, although this practice remains common. [13] [14] [15] [16] [17] Prophylactic antibiotics, when used, should cover methicillinsensitive S. aureus and Pseudomonas, the two most common isolates in this case series and two of the most common isolates in the series by Halvorson et al. 8 It should also cover methicillin-resistant Staphylococcus, coagulase-negative Staphylococcus, Streptococcus, and Enterobacter. For our practice, doxycycline is a well-tolerated, inexpensive, and broadly effective antibiotic to limit these breast implant-associated infections. 18 This study has limitations. The primary limitation is the retrospective case series design, which precluded a comparison group and limited the granularity of some data. Although this study is the largest series of its type to date, it is still fairly small (48 patients with the intervention of interest), and the likelihood of type II error (missing a true difference or association) is high. This study included multiple surgeons, making it more broadly generalizable but also introducing additional variability that may mask associations. This study also spanned 2003 to 2013, a period that saw the popularization of the use of acellular dermal matrices in breast reconstruction. We stopped analyzing patients with index primary tissue expander placement after 2013 to ensure a longer follow-up period; however, this may have limited the applicability of our results to current surgical practice. Future, prospective studies that better control for patient and surgical variables are warranted to determine whether factors such as smoking, radiation therapy, or complication type (e.g., infection, mastectomy flap necrosis) should dissuade further attempts at breast reconstruction with an implant.
CONCLUSIONS
After tissue expander complications, it is reasonable to offer women a second attempt at tissue expansion and implant placement. These 
